Close

News

Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement

Sandoz has entered into a collaboration agreement with Shanghai Henlius Biotech to co-develop a series of new biosimilars across international markets. The milestone-based transaction carries a total consideration of up to $322m, including near-term payments of up to $100.5m...

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on August 13, 2026, to expand its Forward Deployed Engineering organization to 1,000 engineers by December 2026. This expansion creates the industry’s largest pharma AI engineering initiative, addressing growing customer demand...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US Food and Drug Administration (FDA) has published its proposed commitment letter for the GDUFA IV program. Announced in the Federal Register on Monday alongside details for an upcoming public meeting,...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent laboratory settings, and with that growth comes an increasing need for reliable sourcing practices. Selank, a synthetic peptide studied in neuroscience and behavioral research contexts, is one of many compounds...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture contract to establish a new-generation production facility in Shijiazhuang, China. The collaboration focuses on the manufacturing and global supply of mutually agreed biologics drug substances, with capital contributions structured at...

Bristol Myers Squibb Expands Strategic AI Partnership with Schrödinger

Bristol Myers Squibb has expanded its ongoing strategic partnership with Schrödinger through a new agreement to deploy the agentic AI co-scientist platform, Bunsen, across its research operations. Building upon an established collaboration in which Bristol Myers Squibb already utilizes...

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal chemist may design a compound series that becomes central to a development program without being named in a press release. A clinical scientist may reshape an oncology protocol without appearing...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »